NCT03384082 is a NA clinical trial of hysteroscopic treatment in Arcuate Uterus, sponsored by Fu Xing Hospital, Capital Medical University.

Who is sponsoring NCT03384082?

NCT03384082 is sponsored by Fu Xing Hospital, Capital Medical University.

What drugs are being tested in NCT03384082?

Interventions in NCT03384082: hysteroscopic treatment.

What condition does NCT03384082 study?

NCT03384082 studies Arcuate Uterus.

Is NCT03384082 still recruiting?

NCT03384082 is currently status unknown. Last updated 5 March 2020.

Last reviewed 2020-03-05 · How we verify

NCT03384082

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomised Controlled Trial of Hysteroscopic Resection of Mild Septum/Arcuate Uteri.

Status unknown NA Last updated 5 March 2020

What this trial tests

NA trial testing hysteroscopic treatment in Arcuate Uterus in 82 participants. Status unknown.

Timeline

22 February 2019

Primary endpoint
1 January 2021

1 January 2022

Quick facts

Lead sponsor	Fu Xing Hospital, Capital Medical University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	82
Start date	22 February 2019
Primary completion	1 January 2021
Estimated completion	1 January 2022
Sites	1 location across China

Drugs / interventions tested

hysteroscopic treatment

Conditions studied

Arcuate Uterus — all drugs for Arcuate Uterus →

Sponsor

Fu Xing Hospital, Capital Medical University

Who can join

Adults 25 to 40, female only, with Arcuate Uterus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

At least 82 cases of recurrent miscarriage women with a diagnosis of arcuate uterus, confirmed by three-dimensional intra-vaginal sonography (3D-TVS) and hysteroscopy, will be recruited. The subjects will be randomly divided into two groups, the experimental group will be given hysteroscopic treatment, the control group will receive no treatment. The pregnancy rates (\>12 weeks) of the two groups will befollowed and compared.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Fu Xing Hospital, Capital Medical University trials

Trials by the same sponsor.

NCT06862089 — A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV · recruiting
NCT06608407 — Platelet Rich Plasma in the Prevention of Adhesion Reformation · NA · enrolling by invitation
NCT05085067 — The Efficacy of Auto-cross Linked Hyaluronic Acid Gel in the Prevention of Adhesion Reformation After Hysteroscopic Rese · NA · recruiting
NCT04835272 — Comparison of the Decannulation Protocol With Suctioning and Capping in Severe Acquired Brain Injury Patients · NA · unknown
NCT04930913 — Three-dimensional Ultrasound Applying in Assessment of Intrauterine Adhesions · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03384082 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fu Xing Hospital, Capital Medical University
Last refreshed: 5 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03384082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing